Theranostics-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2255732, encodeId=2be02255e3291, content=刚投稿两天，一直显示in progress，而不是under review，不知道是不是没有编辑处理，有和我一样状态的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cb95454789, createdName=ms1000002058344313, createdTime=Wed Mar 12 11:27:36 CST 2025, time=2025-03-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2253083, encodeId=53af225308393, content=偏重的研究方向：检测诊断 经验分享：2025年昨天投的，请教一下一般多久知道送不送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb49508443, createdName=ms2000000301430316, createdTime=Sat Feb 22 13:14:17 CST 2025, time=2025-02-22, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2253319, encodeId=162e225331913, content=暂无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/06/05/85b8806981732e640f738d1aebefae1c.jpg, createdBy=e82a2070394, createdName=温和的常常, createdTime=Mon Feb 24 12:15:57 CST 2025, time=2025-02-24, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2235716, encodeId=c6d52235e168e, content=请教一下大家，注册的时候提供的edu邮箱，显示Student or casual emails are not acceptable. Please ask your supervisor to submit manuscript.163邮箱也不接受，该用什么邮箱呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b358532027, createdName=ms1000000659538220, createdTime=Thu Nov 07 16:04:00 CST 2024, time=2024-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2249375, encodeId=eea222493e578, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：即时影响因子12.8。影响因子稳步有升，非常不错的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Jan 23 23:01:17 CST 2025, time=2025-01-23, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2235378, encodeId=e38222353e823, content=偏重的研究方向：生物医学 经验分享：10.2投稿直接under review 邀请到3个审稿人 11.3收到大修意见 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Tue Nov 05 23:06:04 CST 2024, time=2024-11-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240125, encodeId=686922401250b, content=一本多学科期刊，主要发表体外诊断、分子成像、分子治疗等领域的创新性研究文章。 该期刊的拒稿率较高，通常在80-90%之间，审稿速度还挺较快多，平均从投稿到录用大约需要4个月左右。 研究论文、综述、短篇研究通讯、其他4500澳元；信件、勘误2250澳元（费用有时会发生变化，大家到时还是以官网最新信息为准）。 注册投稿系统时，注意作者名字不能更改，且需要绑定单位邮箱，126和QQ邮箱等不可用，到时这些大家都要提前申请准备好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 23:01:56 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2237430, encodeId=c739223e430d0, content=偏重的研究方向：治疗 经验分享：我10.26提交了，10.31Replace消失了，11.15收到两个审稿人的10个意见，我导师说是大修。编辑写的邮件里让我回答审稿人意见后，重新提交。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Sun Nov 17 13:13:41 CST 2024, time=2024-11-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2235090, encodeId=30ce223509027, content=偏重的研究方向：治疗 经验分享：2024.10.26周六下午投稿，2024.10.31投稿界面手稿后面的Replace消失。应该是送了外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Mon Nov 04 13:22:38 CST 2024, time=2024-11-04, status=1, ipAttribution=上海)]

2025-03-12 ms1000002058344313 来自辽宁省

刚投稿两天，一直显示in progress，而不是under review，不知道是不是没有编辑处理，有和我一样状态的吗

5 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2255732, encodeId=2be02255e3291, content=刚投稿两天，一直显示in progress，而不是under review，不知道是不是没有编辑处理，有和我一样状态的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cb95454789, createdName=ms1000002058344313, createdTime=Wed Mar 12 11:27:36 CST 2025, time=2025-03-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2253083, encodeId=53af225308393, content=偏重的研究方向：检测诊断 经验分享：2025年昨天投的，请教一下一般多久知道送不送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb49508443, createdName=ms2000000301430316, createdTime=Sat Feb 22 13:14:17 CST 2025, time=2025-02-22, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2253319, encodeId=162e225331913, content=暂无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/06/05/85b8806981732e640f738d1aebefae1c.jpg, createdBy=e82a2070394, createdName=温和的常常, createdTime=Mon Feb 24 12:15:57 CST 2025, time=2025-02-24, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2235716, encodeId=c6d52235e168e, content=请教一下大家，注册的时候提供的edu邮箱，显示Student or casual emails are not acceptable. Please ask your supervisor to submit manuscript.163邮箱也不接受，该用什么邮箱呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b358532027, createdName=ms1000000659538220, createdTime=Thu Nov 07 16:04:00 CST 2024, time=2024-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2249375, encodeId=eea222493e578, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：即时影响因子12.8。影响因子稳步有升，非常不错的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Jan 23 23:01:17 CST 2025, time=2025-01-23, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2235378, encodeId=e38222353e823, content=偏重的研究方向：生物医学 经验分享：10.2投稿直接under review 邀请到3个审稿人 11.3收到大修意见 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Tue Nov 05 23:06:04 CST 2024, time=2024-11-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240125, encodeId=686922401250b, content=一本多学科期刊，主要发表体外诊断、分子成像、分子治疗等领域的创新性研究文章。 该期刊的拒稿率较高，通常在80-90%之间，审稿速度还挺较快多，平均从投稿到录用大约需要4个月左右。 研究论文、综述、短篇研究通讯、其他4500澳元；信件、勘误2250澳元（费用有时会发生变化，大家到时还是以官网最新信息为准）。 注册投稿系统时，注意作者名字不能更改，且需要绑定单位邮箱，126和QQ邮箱等不可用，到时这些大家都要提前申请准备好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 23:01:56 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2237430, encodeId=c739223e430d0, content=偏重的研究方向：治疗 经验分享：我10.26提交了，10.31Replace消失了，11.15收到两个审稿人的10个意见，我导师说是大修。编辑写的邮件里让我回答审稿人意见后，重新提交。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Sun Nov 17 13:13:41 CST 2024, time=2024-11-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2235090, encodeId=30ce223509027, content=偏重的研究方向：治疗 经验分享：2024.10.26周六下午投稿，2024.10.31投稿界面手稿后面的Replace消失。应该是送了外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Mon Nov 04 13:22:38 CST 2024, time=2024-11-04, status=1, ipAttribution=上海)]

2025-02-22 ms2000000301430316 来自吉林省

偏重的研究方向：检测诊断
经验分享：2025年昨天投的，请教一下一般多久知道送不送审啊

3 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2255732, encodeId=2be02255e3291, content=刚投稿两天，一直显示in progress，而不是under review，不知道是不是没有编辑处理，有和我一样状态的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cb95454789, createdName=ms1000002058344313, createdTime=Wed Mar 12 11:27:36 CST 2025, time=2025-03-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2253083, encodeId=53af225308393, content=偏重的研究方向：检测诊断 经验分享：2025年昨天投的，请教一下一般多久知道送不送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb49508443, createdName=ms2000000301430316, createdTime=Sat Feb 22 13:14:17 CST 2025, time=2025-02-22, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2253319, encodeId=162e225331913, content=暂无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/06/05/85b8806981732e640f738d1aebefae1c.jpg, createdBy=e82a2070394, createdName=温和的常常, createdTime=Mon Feb 24 12:15:57 CST 2025, time=2025-02-24, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2235716, encodeId=c6d52235e168e, content=请教一下大家，注册的时候提供的edu邮箱，显示Student or casual emails are not acceptable. Please ask your supervisor to submit manuscript.163邮箱也不接受，该用什么邮箱呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b358532027, createdName=ms1000000659538220, createdTime=Thu Nov 07 16:04:00 CST 2024, time=2024-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2249375, encodeId=eea222493e578, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：即时影响因子12.8。影响因子稳步有升，非常不错的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Jan 23 23:01:17 CST 2025, time=2025-01-23, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2235378, encodeId=e38222353e823, content=偏重的研究方向：生物医学 经验分享：10.2投稿直接under review 邀请到3个审稿人 11.3收到大修意见 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Tue Nov 05 23:06:04 CST 2024, time=2024-11-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240125, encodeId=686922401250b, content=一本多学科期刊，主要发表体外诊断、分子成像、分子治疗等领域的创新性研究文章。 该期刊的拒稿率较高，通常在80-90%之间，审稿速度还挺较快多，平均从投稿到录用大约需要4个月左右。 研究论文、综述、短篇研究通讯、其他4500澳元；信件、勘误2250澳元（费用有时会发生变化，大家到时还是以官网最新信息为准）。 注册投稿系统时，注意作者名字不能更改，且需要绑定单位邮箱，126和QQ邮箱等不可用，到时这些大家都要提前申请准备好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 23:01:56 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2237430, encodeId=c739223e430d0, content=偏重的研究方向：治疗 经验分享：我10.26提交了，10.31Replace消失了，11.15收到两个审稿人的10个意见，我导师说是大修。编辑写的邮件里让我回答审稿人意见后，重新提交。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Sun Nov 17 13:13:41 CST 2024, time=2024-11-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2235090, encodeId=30ce223509027, content=偏重的研究方向：治疗 经验分享：2024.10.26周六下午投稿，2024.10.31投稿界面手稿后面的Replace消失。应该是送了外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Mon Nov 04 13:22:38 CST 2024, time=2024-11-04, status=1, ipAttribution=上海)]

2025-02-24 温和的常常来自陕西省

暂无

4 0

[GetPortalCommentsPageByObjectIdResponse(id=2255732, encodeId=2be02255e3291, content=刚投稿两天，一直显示in progress，而不是under review，不知道是不是没有编辑处理，有和我一样状态的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cb95454789, createdName=ms1000002058344313, createdTime=Wed Mar 12 11:27:36 CST 2025, time=2025-03-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2253083, encodeId=53af225308393, content=偏重的研究方向：检测诊断 经验分享：2025年昨天投的，请教一下一般多久知道送不送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb49508443, createdName=ms2000000301430316, createdTime=Sat Feb 22 13:14:17 CST 2025, time=2025-02-22, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2253319, encodeId=162e225331913, content=暂无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/06/05/85b8806981732e640f738d1aebefae1c.jpg, createdBy=e82a2070394, createdName=温和的常常, createdTime=Mon Feb 24 12:15:57 CST 2025, time=2025-02-24, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2235716, encodeId=c6d52235e168e, content=请教一下大家，注册的时候提供的edu邮箱，显示Student or casual emails are not acceptable. Please ask your supervisor to submit manuscript.163邮箱也不接受，该用什么邮箱呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b358532027, createdName=ms1000000659538220, createdTime=Thu Nov 07 16:04:00 CST 2024, time=2024-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2249375, encodeId=eea222493e578, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：即时影响因子12.8。影响因子稳步有升，非常不错的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Jan 23 23:01:17 CST 2025, time=2025-01-23, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2235378, encodeId=e38222353e823, content=偏重的研究方向：生物医学 经验分享：10.2投稿直接under review 邀请到3个审稿人 11.3收到大修意见 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Tue Nov 05 23:06:04 CST 2024, time=2024-11-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240125, encodeId=686922401250b, content=一本多学科期刊，主要发表体外诊断、分子成像、分子治疗等领域的创新性研究文章。 该期刊的拒稿率较高，通常在80-90%之间，审稿速度还挺较快多，平均从投稿到录用大约需要4个月左右。 研究论文、综述、短篇研究通讯、其他4500澳元；信件、勘误2250澳元（费用有时会发生变化，大家到时还是以官网最新信息为准）。 注册投稿系统时，注意作者名字不能更改，且需要绑定单位邮箱，126和QQ邮箱等不可用，到时这些大家都要提前申请准备好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 23:01:56 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2237430, encodeId=c739223e430d0, content=偏重的研究方向：治疗 经验分享：我10.26提交了，10.31Replace消失了，11.15收到两个审稿人的10个意见，我导师说是大修。编辑写的邮件里让我回答审稿人意见后，重新提交。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Sun Nov 17 13:13:41 CST 2024, time=2024-11-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2235090, encodeId=30ce223509027, content=偏重的研究方向：治疗 经验分享：2024.10.26周六下午投稿，2024.10.31投稿界面手稿后面的Replace消失。应该是送了外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Mon Nov 04 13:22:38 CST 2024, time=2024-11-04, status=1, ipAttribution=上海)]

2024-11-07 ms1000000659538220 来自上海

请教一下大家，注册的时候提供的edu邮箱，显示Student or casual emails are not acceptable. Please ask your supervisor to submit manuscript.163邮箱也不接受，该用什么邮箱呀

29 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2255732, encodeId=2be02255e3291, content=刚投稿两天，一直显示in progress，而不是under review，不知道是不是没有编辑处理，有和我一样状态的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cb95454789, createdName=ms1000002058344313, createdTime=Wed Mar 12 11:27:36 CST 2025, time=2025-03-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2253083, encodeId=53af225308393, content=偏重的研究方向：检测诊断 经验分享：2025年昨天投的，请教一下一般多久知道送不送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb49508443, createdName=ms2000000301430316, createdTime=Sat Feb 22 13:14:17 CST 2025, time=2025-02-22, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2253319, encodeId=162e225331913, content=暂无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/06/05/85b8806981732e640f738d1aebefae1c.jpg, createdBy=e82a2070394, createdName=温和的常常, createdTime=Mon Feb 24 12:15:57 CST 2025, time=2025-02-24, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2235716, encodeId=c6d52235e168e, content=请教一下大家，注册的时候提供的edu邮箱，显示Student or casual emails are not acceptable. Please ask your supervisor to submit manuscript.163邮箱也不接受，该用什么邮箱呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b358532027, createdName=ms1000000659538220, createdTime=Thu Nov 07 16:04:00 CST 2024, time=2024-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2249375, encodeId=eea222493e578, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：即时影响因子12.8。影响因子稳步有升，非常不错的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Jan 23 23:01:17 CST 2025, time=2025-01-23, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2235378, encodeId=e38222353e823, content=偏重的研究方向：生物医学 经验分享：10.2投稿直接under review 邀请到3个审稿人 11.3收到大修意见 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Tue Nov 05 23:06:04 CST 2024, time=2024-11-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240125, encodeId=686922401250b, content=一本多学科期刊，主要发表体外诊断、分子成像、分子治疗等领域的创新性研究文章。 该期刊的拒稿率较高，通常在80-90%之间，审稿速度还挺较快多，平均从投稿到录用大约需要4个月左右。 研究论文、综述、短篇研究通讯、其他4500澳元；信件、勘误2250澳元（费用有时会发生变化，大家到时还是以官网最新信息为准）。 注册投稿系统时，注意作者名字不能更改，且需要绑定单位邮箱，126和QQ邮箱等不可用，到时这些大家都要提前申请准备好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 23:01:56 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2237430, encodeId=c739223e430d0, content=偏重的研究方向：治疗 经验分享：我10.26提交了，10.31Replace消失了，11.15收到两个审稿人的10个意见，我导师说是大修。编辑写的邮件里让我回答审稿人意见后，重新提交。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Sun Nov 17 13:13:41 CST 2024, time=2024-11-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2235090, encodeId=30ce223509027, content=偏重的研究方向：治疗 经验分享：2024.10.26周六下午投稿，2024.10.31投稿界面手稿后面的Replace消失。应该是送了外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Mon Nov 04 13:22:38 CST 2024, time=2024-11-04, status=1, ipAttribution=上海)]

2024-05-29 ms2000000210233780 来自重庆

请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！

114 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2255732, encodeId=2be02255e3291, content=刚投稿两天，一直显示in progress，而不是under review，不知道是不是没有编辑处理，有和我一样状态的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cb95454789, createdName=ms1000002058344313, createdTime=Wed Mar 12 11:27:36 CST 2025, time=2025-03-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2253083, encodeId=53af225308393, content=偏重的研究方向：检测诊断 经验分享：2025年昨天投的，请教一下一般多久知道送不送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb49508443, createdName=ms2000000301430316, createdTime=Sat Feb 22 13:14:17 CST 2025, time=2025-02-22, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2253319, encodeId=162e225331913, content=暂无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/06/05/85b8806981732e640f738d1aebefae1c.jpg, createdBy=e82a2070394, createdName=温和的常常, createdTime=Mon Feb 24 12:15:57 CST 2025, time=2025-02-24, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2235716, encodeId=c6d52235e168e, content=请教一下大家，注册的时候提供的edu邮箱，显示Student or casual emails are not acceptable. Please ask your supervisor to submit manuscript.163邮箱也不接受，该用什么邮箱呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b358532027, createdName=ms1000000659538220, createdTime=Thu Nov 07 16:04:00 CST 2024, time=2024-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2249375, encodeId=eea222493e578, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：即时影响因子12.8。影响因子稳步有升，非常不错的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Jan 23 23:01:17 CST 2025, time=2025-01-23, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2235378, encodeId=e38222353e823, content=偏重的研究方向：生物医学 经验分享：10.2投稿直接under review 邀请到3个审稿人 11.3收到大修意见 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Tue Nov 05 23:06:04 CST 2024, time=2024-11-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240125, encodeId=686922401250b, content=一本多学科期刊，主要发表体外诊断、分子成像、分子治疗等领域的创新性研究文章。 该期刊的拒稿率较高，通常在80-90%之间，审稿速度还挺较快多，平均从投稿到录用大约需要4个月左右。 研究论文、综述、短篇研究通讯、其他4500澳元；信件、勘误2250澳元（费用有时会发生变化，大家到时还是以官网最新信息为准）。 注册投稿系统时，注意作者名字不能更改，且需要绑定单位邮箱，126和QQ邮箱等不可用，到时这些大家都要提前申请准备好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 23:01:56 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2237430, encodeId=c739223e430d0, content=偏重的研究方向：治疗 经验分享：我10.26提交了，10.31Replace消失了，11.15收到两个审稿人的10个意见，我导师说是大修。编辑写的邮件里让我回答审稿人意见后，重新提交。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Sun Nov 17 13:13:41 CST 2024, time=2024-11-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2235090, encodeId=30ce223509027, content=偏重的研究方向：治疗 经验分享：2024.10.26周六下午投稿，2024.10.31投稿界面手稿后面的Replace消失。应该是送了外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Mon Nov 04 13:22:38 CST 2024, time=2024-11-04, status=1, ipAttribution=上海)]

2025-01-23 1811e984f8m 来自安徽省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：即时影响因子12.8。影响因子稳步有升，非常不错的期刊。

33 0

[GetPortalCommentsPageByObjectIdResponse(id=2255732, encodeId=2be02255e3291, content=刚投稿两天，一直显示in progress，而不是under review，不知道是不是没有编辑处理，有和我一样状态的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cb95454789, createdName=ms1000002058344313, createdTime=Wed Mar 12 11:27:36 CST 2025, time=2025-03-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2253083, encodeId=53af225308393, content=偏重的研究方向：检测诊断 经验分享：2025年昨天投的，请教一下一般多久知道送不送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb49508443, createdName=ms2000000301430316, createdTime=Sat Feb 22 13:14:17 CST 2025, time=2025-02-22, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2253319, encodeId=162e225331913, content=暂无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/06/05/85b8806981732e640f738d1aebefae1c.jpg, createdBy=e82a2070394, createdName=温和的常常, createdTime=Mon Feb 24 12:15:57 CST 2025, time=2025-02-24, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2235716, encodeId=c6d52235e168e, content=请教一下大家，注册的时候提供的edu邮箱，显示Student or casual emails are not acceptable. Please ask your supervisor to submit manuscript.163邮箱也不接受，该用什么邮箱呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b358532027, createdName=ms1000000659538220, createdTime=Thu Nov 07 16:04:00 CST 2024, time=2024-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2249375, encodeId=eea222493e578, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：即时影响因子12.8。影响因子稳步有升，非常不错的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Jan 23 23:01:17 CST 2025, time=2025-01-23, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2235378, encodeId=e38222353e823, content=偏重的研究方向：生物医学 经验分享：10.2投稿直接under review 邀请到3个审稿人 11.3收到大修意见 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Tue Nov 05 23:06:04 CST 2024, time=2024-11-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240125, encodeId=686922401250b, content=一本多学科期刊，主要发表体外诊断、分子成像、分子治疗等领域的创新性研究文章。 该期刊的拒稿率较高，通常在80-90%之间，审稿速度还挺较快多，平均从投稿到录用大约需要4个月左右。 研究论文、综述、短篇研究通讯、其他4500澳元；信件、勘误2250澳元（费用有时会发生变化，大家到时还是以官网最新信息为准）。 注册投稿系统时，注意作者名字不能更改，且需要绑定单位邮箱，126和QQ邮箱等不可用，到时这些大家都要提前申请准备好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 23:01:56 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2237430, encodeId=c739223e430d0, content=偏重的研究方向：治疗 经验分享：我10.26提交了，10.31Replace消失了，11.15收到两个审稿人的10个意见，我导师说是大修。编辑写的邮件里让我回答审稿人意见后，重新提交。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Sun Nov 17 13:13:41 CST 2024, time=2024-11-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2235090, encodeId=30ce223509027, content=偏重的研究方向：治疗 经验分享：2024.10.26周六下午投稿，2024.10.31投稿界面手稿后面的Replace消失。应该是送了外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Mon Nov 04 13:22:38 CST 2024, time=2024-11-04, status=1, ipAttribution=上海)]

2024-11-05 ms1000001788822131 来自上海

偏重的研究方向：生物医学
经验分享：10.2投稿直接under review
邀请到3个审稿人
11.3收到大修意见

38 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2255732, encodeId=2be02255e3291, content=刚投稿两天，一直显示in progress，而不是under review，不知道是不是没有编辑处理，有和我一样状态的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cb95454789, createdName=ms1000002058344313, createdTime=Wed Mar 12 11:27:36 CST 2025, time=2025-03-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2253083, encodeId=53af225308393, content=偏重的研究方向：检测诊断 经验分享：2025年昨天投的，请教一下一般多久知道送不送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb49508443, createdName=ms2000000301430316, createdTime=Sat Feb 22 13:14:17 CST 2025, time=2025-02-22, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2253319, encodeId=162e225331913, content=暂无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/06/05/85b8806981732e640f738d1aebefae1c.jpg, createdBy=e82a2070394, createdName=温和的常常, createdTime=Mon Feb 24 12:15:57 CST 2025, time=2025-02-24, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2235716, encodeId=c6d52235e168e, content=请教一下大家，注册的时候提供的edu邮箱，显示Student or casual emails are not acceptable. Please ask your supervisor to submit manuscript.163邮箱也不接受，该用什么邮箱呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b358532027, createdName=ms1000000659538220, createdTime=Thu Nov 07 16:04:00 CST 2024, time=2024-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2249375, encodeId=eea222493e578, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：即时影响因子12.8。影响因子稳步有升，非常不错的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Jan 23 23:01:17 CST 2025, time=2025-01-23, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2235378, encodeId=e38222353e823, content=偏重的研究方向：生物医学 经验分享：10.2投稿直接under review 邀请到3个审稿人 11.3收到大修意见 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Tue Nov 05 23:06:04 CST 2024, time=2024-11-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240125, encodeId=686922401250b, content=一本多学科期刊，主要发表体外诊断、分子成像、分子治疗等领域的创新性研究文章。 该期刊的拒稿率较高，通常在80-90%之间，审稿速度还挺较快多，平均从投稿到录用大约需要4个月左右。 研究论文、综述、短篇研究通讯、其他4500澳元；信件、勘误2250澳元（费用有时会发生变化，大家到时还是以官网最新信息为准）。 注册投稿系统时，注意作者名字不能更改，且需要绑定单位邮箱，126和QQ邮箱等不可用，到时这些大家都要提前申请准备好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 23:01:56 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2237430, encodeId=c739223e430d0, content=偏重的研究方向：治疗 经验分享：我10.26提交了，10.31Replace消失了，11.15收到两个审稿人的10个意见，我导师说是大修。编辑写的邮件里让我回答审稿人意见后，重新提交。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Sun Nov 17 13:13:41 CST 2024, time=2024-11-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2235090, encodeId=30ce223509027, content=偏重的研究方向：治疗 经验分享：2024.10.26周六下午投稿，2024.10.31投稿界面手稿后面的Replace消失。应该是送了外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Mon Nov 04 13:22:38 CST 2024, time=2024-11-04, status=1, ipAttribution=上海)]

2024-11-30 ms2000001788822132 来自上海

一本多学科期刊，主要发表体外诊断、分子成像、分子治疗等领域的创新性研究文章。
该期刊的拒稿率较高，通常在80-90%之间，审稿速度还挺较快多，平均从投稿到录用大约需要4个月左右。
研究论文、综述、短篇研究通讯、其他4500澳元；信件、勘误2250澳元（费用有时会发生变化，大家到时还是以官网最新信息为准）。
注册投稿系统时，注意作者名字不能更改，且需要绑定单位邮箱，126和QQ邮箱等不可用，到时这些大家都要提前申请准备好。

30 0

[GetPortalCommentsPageByObjectIdResponse(id=2255732, encodeId=2be02255e3291, content=刚投稿两天，一直显示in progress，而不是under review，不知道是不是没有编辑处理，有和我一样状态的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cb95454789, createdName=ms1000002058344313, createdTime=Wed Mar 12 11:27:36 CST 2025, time=2025-03-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2253083, encodeId=53af225308393, content=偏重的研究方向：检测诊断 经验分享：2025年昨天投的，请教一下一般多久知道送不送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb49508443, createdName=ms2000000301430316, createdTime=Sat Feb 22 13:14:17 CST 2025, time=2025-02-22, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2253319, encodeId=162e225331913, content=暂无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/06/05/85b8806981732e640f738d1aebefae1c.jpg, createdBy=e82a2070394, createdName=温和的常常, createdTime=Mon Feb 24 12:15:57 CST 2025, time=2025-02-24, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2235716, encodeId=c6d52235e168e, content=请教一下大家，注册的时候提供的edu邮箱，显示Student or casual emails are not acceptable. Please ask your supervisor to submit manuscript.163邮箱也不接受，该用什么邮箱呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b358532027, createdName=ms1000000659538220, createdTime=Thu Nov 07 16:04:00 CST 2024, time=2024-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2249375, encodeId=eea222493e578, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：即时影响因子12.8。影响因子稳步有升，非常不错的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Jan 23 23:01:17 CST 2025, time=2025-01-23, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2235378, encodeId=e38222353e823, content=偏重的研究方向：生物医学 经验分享：10.2投稿直接under review 邀请到3个审稿人 11.3收到大修意见 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Tue Nov 05 23:06:04 CST 2024, time=2024-11-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240125, encodeId=686922401250b, content=一本多学科期刊，主要发表体外诊断、分子成像、分子治疗等领域的创新性研究文章。 该期刊的拒稿率较高，通常在80-90%之间，审稿速度还挺较快多，平均从投稿到录用大约需要4个月左右。 研究论文、综述、短篇研究通讯、其他4500澳元；信件、勘误2250澳元（费用有时会发生变化，大家到时还是以官网最新信息为准）。 注册投稿系统时，注意作者名字不能更改，且需要绑定单位邮箱，126和QQ邮箱等不可用，到时这些大家都要提前申请准备好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 23:01:56 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2237430, encodeId=c739223e430d0, content=偏重的研究方向：治疗 经验分享：我10.26提交了，10.31Replace消失了，11.15收到两个审稿人的10个意见，我导师说是大修。编辑写的邮件里让我回答审稿人意见后，重新提交。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Sun Nov 17 13:13:41 CST 2024, time=2024-11-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2235090, encodeId=30ce223509027, content=偏重的研究方向：治疗 经验分享：2024.10.26周六下午投稿，2024.10.31投稿界面手稿后面的Replace消失。应该是送了外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Mon Nov 04 13:22:38 CST 2024, time=2024-11-04, status=1, ipAttribution=上海)]

2024-11-17 ms2000001152791108 来自上海

偏重的研究方向：治疗
经验分享：我10.26提交了，10.31Replace消失了，11.15收到两个审稿人的10个意见，我导师说是大修。编辑写的邮件里让我回答审稿人意见后，重新提交。

48 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2255732, encodeId=2be02255e3291, content=刚投稿两天，一直显示in progress，而不是under review，不知道是不是没有编辑处理，有和我一样状态的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cb95454789, createdName=ms1000002058344313, createdTime=Wed Mar 12 11:27:36 CST 2025, time=2025-03-12, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2253083, encodeId=53af225308393, content=偏重的研究方向：检测诊断 经验分享：2025年昨天投的，请教一下一般多久知道送不送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb49508443, createdName=ms2000000301430316, createdTime=Sat Feb 22 13:14:17 CST 2025, time=2025-02-22, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2253319, encodeId=162e225331913, content=暂无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/06/05/85b8806981732e640f738d1aebefae1c.jpg, createdBy=e82a2070394, createdName=温和的常常, createdTime=Mon Feb 24 12:15:57 CST 2025, time=2025-02-24, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2235716, encodeId=c6d52235e168e, content=请教一下大家，注册的时候提供的edu邮箱，显示Student or casual emails are not acceptable. Please ask your supervisor to submit manuscript.163邮箱也不接受，该用什么邮箱呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b358532027, createdName=ms1000000659538220, createdTime=Thu Nov 07 16:04:00 CST 2024, time=2024-11-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2249375, encodeId=eea222493e578, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：即时影响因子12.8。影响因子稳步有升，非常不错的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Jan 23 23:01:17 CST 2025, time=2025-01-23, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2235378, encodeId=e38222353e823, content=偏重的研究方向：生物医学 经验分享：10.2投稿直接under review 邀请到3个审稿人 11.3收到大修意见 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Tue Nov 05 23:06:04 CST 2024, time=2024-11-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240125, encodeId=686922401250b, content=一本多学科期刊，主要发表体外诊断、分子成像、分子治疗等领域的创新性研究文章。 该期刊的拒稿率较高，通常在80-90%之间，审稿速度还挺较快多，平均从投稿到录用大约需要4个月左右。 研究论文、综述、短篇研究通讯、其他4500澳元；信件、勘误2250澳元（费用有时会发生变化，大家到时还是以官网最新信息为准）。 注册投稿系统时，注意作者名字不能更改，且需要绑定单位邮箱，126和QQ邮箱等不可用，到时这些大家都要提前申请准备好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 23:01:56 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2237430, encodeId=c739223e430d0, content=偏重的研究方向：治疗 经验分享：我10.26提交了，10.31Replace消失了，11.15收到两个审稿人的10个意见，我导师说是大修。编辑写的邮件里让我回答审稿人意见后，重新提交。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Sun Nov 17 13:13:41 CST 2024, time=2024-11-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2235090, encodeId=30ce223509027, content=偏重的研究方向：治疗 经验分享：2024.10.26周六下午投稿，2024.10.31投稿界面手稿后面的Replace消失。应该是送了外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=525d8459079, createdName=ms2000001152791108, createdTime=Mon Nov 04 13:22:38 CST 2024, time=2024-11-04, status=1, ipAttribution=上海)]

2024-11-04 ms2000001152791108 来自上海

偏重的研究方向：治疗
经验分享：2024.10.26周六下午投稿，2024.10.31投稿界面手稿后面的Replace消失。应该是送了外审。

26 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务